Diaceutics (LON:DXRX) Issues Earnings Results

Diaceutics (LON:DXRX) posted its earnings results on Tuesday. The company reported GBX (3.27) earnings per share for the quarter, Digital Look Earnings reports. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.

Diaceutics Price Performance

LON:DXRX traded up GBX 16 during trading hours on Tuesday, hitting GBX 186. 1,307,491 shares of the company’s stock traded hands, compared to its average volume of 202,378. The business’s fifty day simple moving average is GBX 145.09 and its two-hundred day simple moving average is GBX 150.64. Diaceutics has a 52 week low of GBX 125 and a 52 week high of GBX 186.90. The firm has a market cap of £157.84 million, a P/E ratio of 1,690.91 and a beta of 0.88. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 price target on shares of Diaceutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics currently has an average rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.